Track Tempus AI, Inc. Class A Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Tempus AI, Inc. Class A Common Stock TEM · Stock Open Tempus AI, Inc. Class A Common Stock in new tab

71.60 USD
P/E
41.79
EPS
-1.06
P/B
29.90
ROE
-37.55
Beta
3.61
Target Price
89.56 USD
Tempus AI, Inc. Class A Common Stock logo

Tempus AI, Inc. Class A Common Stock

🧾 Earnings Recap – Q3 2026

Tempus gained 8.7% after reporting Q3 revenue growth of 23%, positive adjusted EBITDA, and higher 2026 revenue guidance. The quarter’s strongest growth came from oncology volume and Data and Apps, while hereditary cancer testing remains an area to watch.

  • Revenue was $412 million, up 23% year over year; diagnostics contributed $304 million, up 20%, and Data and Apps contributed $108 million, up 33%.
  • Oncology revenue rose 28% to $173 million, with volume up 32%. Hereditary cancer testing revenue was $111 million; management said the business appears poised to do better, but the call excerpt does not provide a 2027 outlook.
  • Adjusted EBITDA was $25.6 million, and cash and marketable securities totaled $854 million at quarter-end.
  • Tempus raised 2026 revenue guidance to $1.6 billion and maintained its expectation of approximately $65 million in adjusted EBITDA.
  • The BMS and Pathos agreements are expected to generate $193 million of additional Data and Apps revenue over approximately five years.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 23, 2027
P/E41.79
EPS-1.06
Book Value2.75
Price to Book29.90
Debt/Equity286.15
% Insiders36.153%
Growth
Revenue Growth0.23%
Estimates
Forward P/E-2078.38
Forward EPS-0.04
Target Mean Price89.56

DCF valuation

Model fair value for Tempus AI, Inc. Class A Common Stock (TEM)
Result
Sign in to run the valuation for TEM.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
18 analysts · consensus Buy · mean target 89.56 USD (low 70.00, high 120.00) · as of 10 Nov 2026
Low 70.00
Mean 89.56
High 120.00
Price 71.60
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Tempus AI, Inc. Class A Common Stock Logo Tempus AI, Inc. Class A Common Stock Analysis (TEM)

United States Healthcare Official Website Stock

Is Tempus AI, Inc. Class A Common Stock a good investment? Tempus AI, Inc. Class A Common Stock (TEM) is currently trading at 71.60 USD. Market analysts have a consensus price target of 89.56 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 41.79. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Tempus AI, Inc. Class A Common Stock is expected to release its next earnings report on Feb. 23, 2027. The market consensus estimate for Forward EPS is -0.04.

Investor FAQ

Does Tempus AI, Inc. Class A Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Tempus AI, Inc. Class A Common Stock?

Tempus AI, Inc. Class A Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 23, 2027. The company currently has a trailing EPS of -1.06.

Company Profile

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Exchange Ticker
TEM
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion